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Abstract
There is conflicting evidence concerning lithium’s effect on renal
function. The aim is to clarify whether lithium affects kidney function
and at what stage of treatment any effect may occur. Systematic review
identified 23 studies split into three groups on which meta-analysis was
performed to identify the following: A) lithium’s effect on renal function
in cross-sectional case-control studies, B) studies of renal function
before and after commencement on lithium, C) studies of longer term
effect in those already established on lithium therapy. Group A showed a
statistically significant increase of 5.7 μmol/L in creatinine in the study
population compared with controls. Group B showed a non-statistically
significant rise in creatinine (2.9 μmol/L) after a mean follow-up of
86 months. Group C showed a statistically significant increase in
creatinine of 7.0 μmol/L over a mean duration of 64 months. An increase
in creatinine of an average of 1.6 μmol/L/year on lithium was also
identified in this group. Any lithium-associated increase in serum
creatinine is quantitatively small and of questionable clinical
significance. However, routine renal function monitoring of patients on
lithium is essential.
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Introduction
Lithium has been used in the treatment of affective disorders
for many years as a mood-stabilizing agent in bipolar affective
disorder. However, there has been an increase in the number of
available mood stabilizers recently, such as sodium valproate,
carbamazepine, olanzapine and quetiapine, giving a wider
range of treatment options for this condition.
Lithium’s effect on the kidney was first observed by Garrod
in the nineteeth century, who noted polyuria and nocturia, with
nephrotoxicity subsequently being reported in the late 1970s
(Lindop and Padfield, 1975). Since this, there have been studies
published that imply that renal dysfunction is a limitation on
the effectiveness of lithium therapy (Johnson, 1998); however,
it is not entirely clear to what extent clinically significant renal
change occurs.
With treatment being guided partly by side-effect profile, a
clear and updated review of studies on lithium’s effect on renal
function is timely. Serum creatinine measurement is a quick,
valid and reliable measure used to accurately estimate glomer-
ular filtration rate (GFR) and therefore a easily useable marker
for practicing physicians.
Method
This systematic review is drawn from a MEDLINE, PUBMED
and PSYCHLIT search using the terms LITHIUM and
RENAL FUNCTION or KIDNEY FUNCTION. All articles
in English were then reviewed and papers then hand searched
for any other studies that met the entry criteria set out below.
Review articles or other articles, for example, those concerning
case studies of less than 10 participants or animal studies, were
not included in the analysis. Given that a number of these stud-
ies were more than a quarter of a century in age, a decision was
taken that it would not be practicable to collect primary data
from all the studies.
The remaining studies were divided into three groups. The
first group enabled a cross-sectional comparison to be made
between lithium users (cases) and age- and sex-matched control
groups not on lithium (group A). The second group of studies
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focused on longitudinal assessment of renal function before and
after commencement on lithium (group B). The final group of
studies prospectively assessed renal function over time for those
who were already established on lithium (group C).
The main outcome measure was the difference in serum cre-
atinine levels between cases and control groups (group A) or
over time (groups B and C). Some studies presented results
for serum creatinine using mg/dL and therefore all results
were converted to the SI measurement unit of μmol/L. The dif-
ference in mean creatinine between the lithium and control
group (and 95% confidence intervals) was calculated for each
study. The before and after studies were analysed as two inde-
pendent samples because data on within-pair differences were
not presented in the study reports. In three studies (Povlsen,
et al., 1992; Walker, et al., 1982; Løkkegaard, et al., 1985),
the standard deviation was not presented but was estimated
from a formula using the range (Hozo, et al., 2005).
Serum creatinine is now a valid and recognised marker to be
used in estimation of GFR as developed within the Modifica-
tion of Diet in Renal Disease (MDRD) study (Levey, et al.,
1999). Levey, et al. (1999) found that using serum creatinine
in an equation along with factors for age, sex and ethnicity
provided a more accurate value for GFR than measuring cre-
atinine clearance or by using the Cockroft and Gault (1976)
formula.
Statistical analysis
Chi-squared tests were used to formally test for heterogeneity
between study estimates. The I2 statistic was used to quantify
the inconsistency between study estimates (Higgins, et al.,
2003). I2 values of greater than 50% indicate moderate hetero-
geneity, whereas values greater than 75% represent severe het-
erogeneity. Publication and selection bias was investigated by
checking for asymmetry in funnel plots (Kirkwood and Sterne,
2003).
As heterogeneity was present, random-effect models were
used to calculate pooled mean estimates (Dersimonian and
Laird, 1986). Study-specific weights in the random-effects
model were calculated and scaled to percentages. All statistical
analyses were performed using STATA 9.0 (Stata Corporation,
College Station, Texas, USA).
The results from group C were also analysed using meta-
regression to investigate the association between the length of
time to follow-up and mean change in creatinine measurements
from baseline to re-testing.
Results
Figure 1 displays the results for the nine cross-sectional studies
that used age- and sex-matched controls. It shows moderate
heterogeneity across the different studies (χ2 = 19.33, df = 8,
P = 0.013, I2 = 59%). The analysis shows an association of
higher creatinine in patients treated with lithium, amounting to
5.7 μmol/L (95% CI 1.7–9.9, P = 0.005). The mean duration of
lithium use in the treated group was 76 months (range 38–141).
Figure 2 shows the results for six studies that measured
serum creatinine before commencement of lithium and then
various time points after beginning treatment. There is border-
line statistically significant heterogeneity across these studies
(χ2 = 15.55, df = 5, P = 0.008, I2 = 68%). Overall, there was a
non-statistically significant (P > 0.1) increase in serum creati-
nine (2.9 μmol/L) at a mean follow-up period of 86 months
(range 16.5–141).
Figure 3 shows the results for the eight studies that assessed
the effect of lithium on renal function in people already estab-
lished on lithium over time, with a mean follow-up period
of 64 months (range 14–132). There is a severe degree of
Control group Lithium group
First author, year n mean (sd) N Mean (sd)
Treatment
duration
(months)
Difference in Serum Creatinine
(mean Lithium group  – mean control 
group)
Difference
(95% CI)
Weight
(%)
Hullin, 1979 30 84 (15) 30 93 (29) 100 9 (-3, 21) 9
Walker, 1982 19 80 (20a) 25 100 (20a) 60 20 (8, 32) 9
Khandelwal, 1983 15 97 (18) 40 106 (19) 56 9 (-2, 20) 9
Decina, 1983 190 110 (19) 190 115 (21) 61 5 (1, 9) 17
Gelenberg, 1987 44 85 (16) 220 94 (20) 38 9 (2, 15) 13
Hetmar, 1987 53 87 (30) 46 99 (20) 96 10 (0, 20) 9
Coskunol, 1997 29 85 (17) 107 81 (14) 54 -4 (-10, 3) 13
Turan, 2002 10 78 (27) 10 75 (16) 80 -3 (-22, 16) 4
Lepkifker, 2004 94 88 (14) 82 90 (17) 141 2 (-3,6) 17
Combined 5.7 (1.7, 9.9)
-30 -15 0 15 30
Lower creatinine in Lithium group Higher creatinine in Lithium group
Figure 1 Forest plot of difference in creatinine (μmol/L) in lithium and control group in cross-sectional studies, ordered by year of publication. Test
for heterogeneity χ2 = 19.33, df = 8, P = 0.013; I2 = 59% (95%CI 13%, 80%); test for overall effect Z = 2.80, P = 0.005. aStandard deviation estimated
from the range (Hozo, et al., 2005).
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heterogeneity across the published studies (χ2 = 28.41, df = 7,
P ≤ 0.001, I2 = 75%). There is evidence of an increase in
serum creatinine levels of 7.0 μmol/L over time (P = 0.045).
Figure 4 shows the results from meta-regression analysis
performed on group C. This shows an increase in creatinine
of an average of 1.6 μmol/L/year on lithium (95% CI 0.9–2.3,
P < 0.001).
Discussion
The main finding from this meta-analysis is one of a small non-
statistically significant rise in serum creatinine in the first years
of lithium treatment that becomes statistically significant with
increasing duration of treatment. When compared with control
patients, an association between lithium usage and higher
serum creatinine was showed. However, the interpretation of
these results is made more difficult by the moderate to severe
degree of heterogeneity. Caution should be used in attempting
to draw conclusions from the published data.
There are various strengths and weaknesses in this meta-
analysis. Strengths include that by separating the studies into
groups we addressed not only whether impairment of kidney
function occurs but also attempted to identify at what stage
of lithium treatment any impairment may begin and also
whether there is any potential progressive decline over time;
that the studies included were derived from a literature search
spanning four decades from 1979 to 2004; that most of the
studies included either had a large number of subjects or a
lengthy follow-up period and that the use of serum creatinine
as a marker for renal impairment is a strength given its ease of
use in routine clinical practice and its incorporation into a
widely used formula for the estimation of GFR (Levey, et al.,
1999).
Weaknesses include the limited number of trials published;
poor retention of subjects in some studies, resulting in the
potential for those whose lithium was stopped due to renal
Before Lithium After Lithium
First author, year
n mean (sd) n mean (sd)
Follow-
up
(months)
Difference in Serum Creatinine 
(mean after  – mean before)
Difference     
(95% CI)
Weight
(%)
Jensen, 1984 13 88 (11) 13 85 (14) 16.5 -3 (-13, 6) 11
Lokkegaard,1985 142 93 (37a) 142 90 (32a) 120 -3 (-11,5) 16
Hetmar, 1986 46 90 (12) 46 97 (19) 97 7 (1, 14) 16
Schou, 1988 39 87 (11) 194 92 (13) 48 5 (1, 8) 21
Povlsen, 1992 53 87 (10b) 10 99 (10b) 96 12 (5, 19) 16
Lepkifker, 2004 114 91 (15) 82 90 (17) 141 -1 (-5, 4) 21
Combined 2.9 (-1.4, 7.4)
-20 -10 0 10 20
Lower Creatinine after 
lithium
Higher Creatinine after 
lithium
Figure 2 Forest plot of difference in creatinine (μmol/L) in before and after studies of lithium, ordered by year of publication. Test for heterogeneity
χ2 = 15.55, df = 5, P = 0.008; I2 = 68% (95%CI 24%, 86%); test for overall effect Z = 1.32, P = 0.19. aStandard deviation estimated from the range
(Hozo, et al., 2005). bMean and standard deviation estimated from the median and range (Hozo, et al., 2005).
Baseline Follow-up
n mean (sd) n mean (sd)
Follow-
up 
(months)
Difference in Serum Creatinine Difference  
(95% CI)
Weight
(%)
Johnson,1984 23 84 (15) 23 97 (44) 24 13 (-6, 32) 8
De Paulo, 1986 40 97 (16) 40 92 (17) 14 -5 (-12, 2) 16
Hetmar, 1987 46 97 (19) 32 99 (20) 24 2 (-7, 11) 15
Waller,1988 28 84 (16) 28 83 (16) 56 -1 (-9, 7) 15
Muir, 1989 18 87 (42) 9 90 (30) 18 3 (-28,34) 5
Hetmar, 1991 46 97 (20) 19 119 (40) 120 22 (7, 37) 8
Kallner, 1995 50 86 (24) 50 101 (20) 120 15 (6, 24) 15
Bendz,2001 137 84 (17) 86 96 (17) 132 12 (7,17) 18
Combined 7.0 (0.2, 13.8)
-15 0 15 30
Lower Creatinine in early Lithium 
group 
Higher Creatinine in late Lithium 
group
First author, year
Figure 3 Forest plot of difference in creatinine (μmol/L) for prospective group previously established on lithium, ordered by year of publication. Test
for heterogeneity χ2 = 28.41, df = 7, P ≤ 0.001; I2 = 75% (95%CI 50%, 88%); test for overall effect Z = 2.01, P = 0.045.
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side effects being excluded; a broad range of follow-up periods
studied, with fewer long-term studies being published; the use
of different laboratory tests for measuring serum creatinine and
the fact that serum creatinine was not the primary outcome
measure for most of the studies. There is also a significant
degree of heterogeneity across the three groups of studies ana-
lysed (I2 = 59, 68, and 75% in groups A, B and C, respectively);
however, approximately 25% of all published meta-analyses
have an I2 value of greater than 50% (Higgins, et al., 2003).
Does lithium lead to increased creatinine levels
compared with controls (group A)?
This analysis compares subjects on lithium with an age- and
sex-matched control group. There are a number of inherent
differences in the designs of these studies including the length
of time patients had been on lithium; presence of control-group
diagnosis and concurrent medication usage. All studies set out
with different primary aims, raising the question of compara-
bility. Heterogeneity was moderate (I2 = 59%), with a statisti-
cally significant (P = 0.005) increase in creatinine levels of
5.7 μmol/L in patients taking lithium when compared with con-
trol patients that were age- and sex-matched.
The largest study in this group is by Decina, et al. (1983),
who clearly set out with the primary aim to use creatinine as a
measure of glomerular renal function. They concluded that
lithium patients had a significantly higher creatinine concentra-
tion than controls even when weight, sex, age and arterial
blood pressure were allowed for.
Khandelwal, et al. (1983) took a much broader look at both
tubular and glomerular function, and although some obvious
effects on renal concentrating capacity were noted, no effect
was shown in GFRs. Similarly, Hullin, et al. (1979), looking
at GFR and renal concentrating capacity, found no evidence
of deterioration of GFR associated with lithium.
Another entirely different approach was undertaken by
Walker, et al. (1982). In this article, the primary outcome mea-
sure was histological change associated with lithium treatment,
whereas change in creatinine in patients on lithium was a sec-
ondary measure. Renal biopsy showed a specific acute revers-
ible change in the tubule in all subjects on lithium and also the
presence of a chronic non-specific interstitial nephropathy in all
patients who were either receiving lithium or who were pre-
lithium treatment but deemed clinically appropriate for lithium
therapy to be given.
Gelenberg, et al. (1987) looked at gender differences and
discovered no significant differences between creatinine levels
and, therefore, glomerular function. However, they did suggest
women have a poorer concentrating capacity, which raises the
potential for a higher risk of renal toxicity from lithium. It
remains unclear whether this represents a gender difference in
vulnerability to lithium or a physiological sex difference in
tubular functioning.
Coskunol, et al. (1997) and Turan, et al. (2002) showed non-
significant findings that seemed to favour lithium, that is, a
trend towards lower creatinine levels with lithium treatment.
This result is of course counter-intuitive.
Is there any change in creatinine levels associated
with early lithium treatment (group B)?
Analysis of these studies suggested potential significant hetero-
geneity. Overall, a small, non-statistically significant, increase
in serum creatinine was shown (2.9 μmol/L). Of the six studies
included in the analysis, three detected no significant change in
plasma creatinine and the other three a statistically significant
increase in plasma creatinine.
Jensen and Rickers’s (1984), small (n = 13) study with a
short follow-up (mean of 16.5 months), detected no significant
change in renal function in patients on lithium. Løkkegaard,
et al. (1985) tried to approach the issue of long standing lithium
therapy by taking a cohort of 142 patients who had been trea-
ted with lithium for more than 5 years (mean 10 years lithium
duration). Overall, their findings are in line with those dis-
cussed above, that is, no significant change was detectable in
plasma creatinine. However, a separate analysis of GFR
showed a slight but significant reduction. Unfortunately, quan-
titative data were not presented in this study, but the authors
suggested that it took 17 years or more for the regression line,
time against GFR, to reach the lower reference limit. Thus, this
study highlights the potential for shorter studies to miss this
longer term effect.
In a more recent study, Lepkifker, et al. (2004) found that
there was no statistically significant increase in serum creati-
nine in the majority of lithium takers; however, they also
noted that 21% of people taking lithium long term develop
renal insufficiency. The majority of these patients showed a
sharp rise in serum creatinine after 11–15 years of treatment
on a background of slowly creeping creatinine levels. This find-
ing would be in keeping with those of Løkkegaard, et al.
(1985).
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Figure 4 Difference in mean against study follow-up in months – Data
from Group C.
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Schou and Vestergaard (1988) started with a large cohort of
patients, but over the 7-year follow-up period, there was a sub-
stantial drop-out rate. Therefore, we used the serum creatinine
measurements of a subgroup of 39 patients who had received
continuous lithium therapy for 4 years. In the main outcome
analysis, lithium did not lead to significant reduction of glo-
merular function. A borderline statistically significant rise in
serum creatinine was detected.
The remaining two studies, Hetmar, et al. (1986) and Povl-
sen, et al. (1992), show a statistically significant rise in serum
creatinine measurements in the first few years of lithium treat-
ment. This difference cannot be accounted for on the basis of
differences in subject age or follow-up periods between studies.
A further study that addressed renal function in early lith-
ium treatment by Smigan, et al. (1984) was not included due to
an apparent error in the published results. The units of mea-
surement used corresponded to non-physiological values for
serum creatinine when converted to μmol/L. Overall, this
study suggested a non-progressive decline on GFR during the
first year of lithium therapy.
Does long-term lithium treatment lead to increased
creatinine (group C)?
In combining studies in this area, the initial aim was to detect
any change in creatinine levels over time in patients on long-
term lithium treatment. The pooled data suggested a
7.0 μmol/L increase in creatinine, which reached statistical sig-
nificance (P = 0.045). Heterogeneity between the studies in this
section was severe, which suggests it is inappropriate to com-
bine these studies. Similar to studies in groups A and B, there is
concern regarding high drop-out rates and a wide range of
study lengths and patient numbers. This obvious difference in
parameters and study design can, of course, account for some
of the heterogeneity.
Johnson, et al. (1984), De Paulo, et al. (1986), Hetmar, et al.
(1987) and Muir, et al. (1989) represent four small, short-term
studies, all concluding that lithium treatment led to no signifi-
cant change in creatinine levels. These studies spanned a maxi-
mum of only 2-year follow-up, which represents a short-term
follow-up period. However, Waller, et al. (1988) published sim-
ilar findings in a longer 5-year study, in which they found no
evidence of elevation of serum creatinine or reduction in creat-
inine clearance.
Opposite findings were showed in the other three studies in
this section Hetmar, et al. (1991), Kallner and Petterson (1995)
and Bendz, et al. (2001). Bendz, et al. (2001) conducted a large
study of 149 patients over 8–12 years. Follow-up rates were
poor, but results highlighted a significant increase in serum cre-
atinine and suggest a decrease in GFR with increasing lithium
treatment over time that would be more than expected from
age alone.
Kallner and Petterson (1995) studied a cohort of 207
patients treated with lithium for between 1 and 30 years.
Renal function tests were available for 50 patients treated for
more than 15 years with lithium. A slight but statistically sig-
nificant increase in serum creatinine was detected by this group
over the 10-year follow-up period. However, age adjusted GFR
changed only little with increasing treatment duration.
Using the same population from a previous study by the
same group (Hetmar, et al., 1986), Hetmar, et al. (1991) con-
ducted a smaller study over a similar period in which creatinine
was found to increase significantly, whereas GFR decreased
significantly; however, this change was dependent on increas-
ing age.
Heterogeneity among the studies in this group was severe.
Much of this can be explained when referring to Figure 4.
Regression analysis showed an increase of 1.6 μmol/L of creat-
inine per year of follow-up. Shorter studies thus detected no
significant changes in renal function, whereas those with longer
term follow of 10 years or more seemed to identify a small,
statistically significant change. The clinical significance of
these findings is discussed below.
Overall, within the broad spectrum of studies and outcomes,
a common message is clear – changes in renal function are
often associated with age, episodes of toxicity and concurrent
illness rather than time on lithium or dose.
Conclusion
Renal insufficiency is clearly a very important potential clinical
side effect of lithium. This is reflected in the inclusion of renal
monitoring in the guidelines for lithium prescribing that have
been published [British National Formulary (BMJ, 2006),
American Psychiatric Association, British Association of
Psychopharmacology, Maudsley prescribing guidelines]. How-
ever, as this review shows, there is limited good robust pub-
lished evidence to support a significant rise in serum creatinine.
This is particularly important for today’s clinicians given the
emergence of other mood stabilizers and a trend away from
using lithium, particularly in the United States, with Blanco,
et al. (2002) showing a statistically significant decline
(P = 0.001) in lithium prescriptions from approximately 50 to
30% during the 1990s in bipolar outpatients. It may be that the
recent decrease in publication of articles relating to lithium and
renal function found here represents a trend away from usage
of lithium.
The majority of published literature shows a reduction in
renal concentrating capacity in the early stages of treatment.
The significance and reversibility of this effect on tubular func-
tion remain unclear. Volume depletion is a cause of reversible
decline in renal function and a risk factor for lithium toxicity.
Episodes of lithium toxicity have been linked with subsequent
deterioration in glomerular function (Johnson, 1998; Walker,
1993) but lithium use itself has no effect on glomerular function
if levels are kept within treatment range (Johnson, 1998).
The effect of changes in dosing regimes and a lowering of
the recommended therapeutic range may potentially be lower-
ing the risk of renal impairment further by limiting the poten-
tial for renal toxicity (Gitlin, 1999).
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In these studies, any lithium-induced decrease in renal func-
tion is quantitatively small. This change is probably clinically
insignificant. However, recent studies of patients with early
chronic kidney disease have identified that small changes in
serum creatinine near the normal range can signify more signif-
icant changes in renal function than were previously envisaged.
For instance, in those with small muscle mass such as an 80-
year-old female, a creatinine that changes reproducibly over
time from 80 to 90 μmol/L reflects a fall in GFR of perhaps
just over 10% from 64 mL/min (45–83 mL/min) to 56 mL/min
(39–73 mL/min) (Levey, et al., 1999). This has to be interpreted
carefully as intra-individual day-to-day variation in serum
creatinine can be just as high as this reflecting meat meals
and hydration status etc. (Preiss, 2006).
National Institute for Clinical Excellence (NICE) guidelines
on Chronic Kidney Disease published in September 2008
define disease progression as ‘a decline in GFR of >5 mL/
min/1.73 m2 within 1 year or less, or >10 mL/min/1.73 m2
within 5 years using a minimum of 3 GFR estimations’
(NICE, 2008). These guidelines can be used to interpret the
clinical importance of the statistically significant changes in
creatinine seen in groups A and C.
In group A, the change in serum creatinine of 5.7 μmol/L
represents an approximate 7 mL/min/1.73 m2 fall in estimated
glomerular filtration rate (eGFR) in the treatment group. As
the average duration of lithium use was 6.3 years, this does
not represent a clinically significant fall in eGFR based on
the above guidelines. Group C showed a 7.0 μmol/L rise in
creatinine over time; this is a fall of approximately
9 mL/min/1.73 m.2 The mean time to follow-up was 5.3 years
in this group. However, given the severe heterogeneity showed
between the studies in group C, caution must be used when
attempting to derive meaningful clinical observations from
this data.
These small changes in renal function cannot be disre-
garded. Lepkifker, et al. (2004) identified a potential subgroup
of long-term lithium (>15 years) users at risk of developing
renal impairment, suggesting a figure as high as 21%. Unfortu-
nately, no studies published to date investigating lithium usage
and serum creatinine have a mean follow-up period of more
than 15 years. Any lithium-associated changes in renal function
have to be weighed against the mental health benefits associ-
ated with lithium prophylaxis.
It is evident from this meta-analysis that renal monitoring
programmes for patients on lithium are important. Although
the identified changes in serum creatinine are small and of lim-
ited clinical significance, we advocate a cautious approach.
Routine renal function monitoring of all patients taking lith-
ium is required to identify the minority at risk of a decline in
renal function.
There is a clear need for a large community-based study of
lithium’s usage, its monitoring and its long-term effects on
renal function.
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